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Left Ventricular
Hypertrophy and Sudden Death
Haider et al. (1) and the editorial by Frohlich (2) remind us of the
poor prognosis conferred by left ventricular hypertrophy (LVH) in
hypertensive subjects. They accurately point out that much work
still remains to be done to elucidate the mechanisms by which
LVH leads to sudden cardiac death and other adverse conse-
quences.
Although considerable research has been directed at cardiac
ultrastructure, electrophysiology and the coronary microcirculation
in LVH, the relationship between hemorheology and hypercoagu-
lability in hypertension, especially if LVH is present, has been
relatively neglected. Although the blood vessels are exposed to
high pressures in hypertension, the main complications of hyper-
tension and LVH (that is, stroke and myocardial infarction) are
paradoxically thrombotic rather than hemorrhagic (3). Indeed, the
hypothesis that hypertension and LVH may confer a hypercoag-
ulable state can be examined by careful reference to Virchow’s triad
(3).
In a high proportion of patients suffering sudden death, post-
mortem examination demonstrates the immediate cause to be
thrombotic occlusion of a major epicardial coronary artery (4).
Indeed, a number of hemorheologic and thrombotic markers have
been shown to be significantly related to, and predictive of,
(thrombotic) cardiovascular events in hypertension (3,5). In keep-
ing with Virchow’s triad for thrombus formation (thrombogen-
esis), patients with hypertension demonstrate abnormalities of
vessel wall (endothelial dysfunction or damage), blood constituents
(abnormal levels of hemostatic factors, platelet activation and
fibrinolysis) and blood flow (rheology and flow reserve), suggesting
that hypertension does confer a prothrombotic or hypercoagulable
state (3). These components appear to be related to target organ
damage and long-term prognosis, and are altered by treatment.
In the Leigh general practice study, for example, hypertensive
subjects with plasma fibrinogen levels .3.5 g/l had a 12-fold
higher cardiovascular risk than those with plasma fibrinogen levels
,2.9 g/l (5). We recently reported that hypertensive patients with
LVH had higher plasma fibrinogen levels compared with those
without LVH; fibrinogen levels were also significantly correlated
with left ventricular mass, left ventricular mass index and left atrial
size (6). Hemorheologic abnormalities, such as increases in whole
blood viscosity or fibrinogen, may account for the reduced coronary
flow noted in LVH.
We believe that further study of hemorheology and hyperco-
agulability in hypertension and of the relationship to LVH would
increase our understanding of the mechanisms by which LVH
leads to sudden death. The main mechanisms for sudden death in
LVH are unlikely to be simply electrophysiologic or arrhythmo-
genic, as suggested by Frolich (2), but are also very likely to be
thrombotic in origin.
Charles G. C. Spencer, MBBS, MRCP
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To Trust or Not To Trust
I am writing in response to two articles recently published by
Watanabe et al. (1,2) in the Journal. The accompanying editorial
(3) highlights the fact that there is debate within the scientific
community concerning the results published by this group of
investigators.
These articles are the latest in a series examining pharmacologic
interventions aimed at preventing nitrate tolerance. The interven-
tions range from angiotensin-converting-enzyme inhibition to
vitamin C, vitamin E and now, carvedilol (1,2,4–9). Measures of
nitrate effects include platelet cyclic GMP responses along with
vascular effects documented by blood pressure and forearm pleth-
ysmography. The results in each case have been striking, with
definitive prevention of tolerance across experimental groups that
include normal volunteers, patients with coronary disease and
those with congestive heart failure. The experimental results are
enviable, with closely matched treatment groups (despite small
sample sizes) and highly consistent results in response to the
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intervention. The findings are potentially important. Nevertheless,
the nature and reproducibly positive results are worrisome. Indeed,
it seems unlikely that this wide spectrum of pharmacologic
interventions would be so successful in solving the vexing problem
of nitrate tolerance.
These comments serve to place more specific concerns in
context. This group initially reported their observations with
vitamin C and vitamin E in abstract form (10,11). In both
citations, the number of subjects studied was the same and the
reported results on two of three study days are identical. These
abstracts were followed by two articles published several months
apart in high profile journals (4,8). The articles detail results
obtained in healthy volunteers and patients with coronary disease,
and in both cases, the same number of patients were studied. These
studies report almost identical data—baseline numbers and nitrate
responses are strikingly similar. Indeed, the figures presented in the
two articles are indistinguishable. It is only from review of numeric
results that one can determine small differences in baseline values
and responses. The identical nature of these results warrants
explanation.
There are also concerns about the reported end points. First, in
multiple previous reports, sublingual nitroglycerin does not in-
crease forearm blood flow as measured by strain gauge plethys-
mography (12–15). The reported platelet cyclic GMP responses
are also problematic. In animals, high concentrations of nitroglyc-
erin are required to increase platelet cyclic GMP, and tolerance
does not develop (16). Since the first report by Watanabe et al. in
1993 (17), no other group has reported platelet cyclic GMP as an
index of in vivo nitrate response in human studies. Recently, using
the same analytic approach as Watanabe et al. (17), we found that
platelet cyclic GMP levels do not change in response to sublingual
nitroglycerin (18).
With these thoughts in mind, we are now presented with two
further articles that suggest tolerance can be prevented with
carvedilol (1,2). I support Dr. Parmley for his open discussion of
the dilemma faced by an Editor. The peer review process remains
an essential part of scientific advancement, and as scientists we
must continue to support it. When presented with surprising, but
potentially important results, our responsibility is to be objective
and, when necessary, to repeat the experiment in an effort to
reproduce the results.
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